ReviewFrontiers in endocrinology2025
The role of protein S-acylation in vascular injury associated with metabolic disorders.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein palmitoylation represents a prevalent form post-translational lipid modification across various organisms. This reversible and dynamic cellular process is significant in regulating the transcription and expression of downstream target genes, as well as in facilitating signal transduction. Consequently, it affects various cellular activities, including innate immunity, inflammation, glucose metabolism, lipid metabolism, and functions of the brain and heart. Vascular injury emerges as a critical target organ affected by complications associated with metabolic diseases, and the palmitoylation modifications are implicated in numerous pathological processes. This review offers an overview of current understanding on protein palmitoylation and palmitic acid, emphasizing the influence of the palmitoylation modification on cellular signal transduction in metabolic diseases and exploring its connection with metabolism-related conditions such as diabetic cardiopathy, diabetic nephropathy, and fatty liver diseases. Palmitoleic acid modification holds great promise for tackling challenges related to drug specificity, off-target effects, and delivery mechanisms in the exploration of targeted palmitoleic acid modification therapy
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.